Company intelligence
AVITA Medical
Transforming lives with innovative ways of healing skin.
About AVITA Medical
AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.
Verified activity
Signals from AVITA Medical
5 published signals
Research & Knowledge
AVITA Medical's flagship product RECELL has been featured in 220 scientific and clinical publications, including over 20 randomized controlled trials.
Reported by AVITA Medical
Presence & Recognition
AVITA Medical is attending the 39th Annual Southern Region Burn Conference in Williamsburg, Virginia from September 10-12, featuring a booth at AVITA Medical booth #39 to showcase its acute wound care portfolio.
Reported by AVITA Medical
Presence & Recognition
AVITA Medical employee Professor Fiona Wood received the Royal Society's 2026 King's Medal for pioneering spray-on-skin technology that transformed burn care globally.
Reported by AVITA Medical
Presence & Recognition
AVITA Medical is hosting a webinar on the American Burn Association highlighting the role of RECELL in managing deep partial-thickness burns on Wednesday, September 2, 2026.
Reported by AVITA Medical
People
AVITA Medical is recruiting for a Senior Manager, Commercial Acceleration to expand the Training & Development team.
Reported by Leigh Spellman